CA2799127C - Compositions et methodes pour traiter une lesion cerebrale traumatique - Google Patents

Compositions et methodes pour traiter une lesion cerebrale traumatique Download PDF

Info

Publication number
CA2799127C
CA2799127C CA2799127A CA2799127A CA2799127C CA 2799127 C CA2799127 C CA 2799127C CA 2799127 A CA2799127 A CA 2799127A CA 2799127 A CA2799127 A CA 2799127A CA 2799127 C CA2799127 C CA 2799127C
Authority
CA
Canada
Prior art keywords
traumatic brain
treating traumatic
compositions
methods
brain injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2799127A
Other languages
English (en)
Other versions
CA2799127A1 (fr
Inventor
Matthew Bennett
Gus Peller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Havn Life Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2799127A priority Critical patent/CA2799127C/fr
Publication of CA2799127A1 publication Critical patent/CA2799127A1/fr
Application granted granted Critical
Publication of CA2799127C publication Critical patent/CA2799127C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La divulgation fournit des compositions pour traiter des blessures traumatiques au cerveau, comme des commotions. Selon un mode de réalisation, la composition comprend de la phosphatidylsérine, de la phosphatidylcholine, de la quercétine, de lastaxanthine, de lacide lipoïque R-alpha, de la N-acétylcystéine, de la taurine, de la L-glutamine, de la carnitine, du D-ribose, de la créatine, de lépigallocatéchine gallate, de la mélatonine, de lextrait de feuilles de ginkgo, de la curcumine et de la L-glycine. La divulgation concerne également des méthodes pour traiter les blessures traumatiques au cerveau, comme les commotions, par ladministration dune quantité efficace des compositions décrites.
CA2799127A 2012-12-18 2012-12-18 Compositions et methodes pour traiter une lesion cerebrale traumatique Active CA2799127C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2799127A CA2799127C (fr) 2012-12-18 2012-12-18 Compositions et methodes pour traiter une lesion cerebrale traumatique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2799127A CA2799127C (fr) 2012-12-18 2012-12-18 Compositions et methodes pour traiter une lesion cerebrale traumatique

Publications (2)

Publication Number Publication Date
CA2799127A1 CA2799127A1 (fr) 2014-06-18
CA2799127C true CA2799127C (fr) 2021-05-18

Family

ID=50972847

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2799127A Active CA2799127C (fr) 2012-12-18 2012-12-18 Compositions et methodes pour traiter une lesion cerebrale traumatique

Country Status (1)

Country Link
CA (1) CA2799127C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003385A1 (fr) * 2022-07-01 2024-01-04 N.V. Nutricia Composition nutritionnelle pour la neurodégénérescence et le traumatisme neurologique

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019036442A1 (fr) * 2017-08-14 2019-02-21 Axcella Health Inc. Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale
IT201900003907A1 (it) * 2019-03-18 2020-09-18 Indena Spa Composizioni comprendenti curcumina e coenzima q10
US20220378716A1 (en) * 2019-10-28 2022-12-01 Cora Therapeutics Inc. Formulation to reduce or prevent oxidative stress damage
CN115944085B (zh) * 2022-12-07 2024-08-09 山东奥博森生物药业股份有限公司 一种功能性益生菌组合物及定量添加装置
WO2025003349A1 (fr) * 2023-06-30 2025-01-02 N.V. Nutricia Composition nutritionnelle pour la neurodégénérescence et le traumatisme neurologique

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003385A1 (fr) * 2022-07-01 2024-01-04 N.V. Nutricia Composition nutritionnelle pour la neurodégénérescence et le traumatisme neurologique

Also Published As

Publication number Publication date
CA2799127A1 (fr) 2014-06-18

Similar Documents

Publication Publication Date Title
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
MX380318B (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
CA2799127C (fr) Compositions et methodes pour traiter une lesion cerebrale traumatique
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
MA34064B1 (fr) Compose heterocyclique
HK1205942A1 (en) Compositions, methods, and kits for regulating energy metabolism
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
TN2015000278A1 (en) Autotaxin inhibitors
MY177344A (en) Compounds and their methods of use
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12015501609A1 (en) Phenicol antibacterials
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
MX2015004362A (es) Derivados de ketamina.
BR112014019399A2 (pt) métodos de tratamento da fibrose
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
MX368876B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
BR112015026292A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da dna-pk, bem como kit
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
GEAP202115056A (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
EA201491426A1 (ru) Новые фармацевтические композиции, содержащие фосфатидилсерин и куркумин

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171215

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226